2022-RA-968-ESGO Immunotherapy response monitoring using personalized circulating tumor DNA analysis in patients with relapsed gynecologic malignancies. (20th October 2022)

• Record Type: Journal Article
• Authors: Castaneda, Kayla; Saldivar, Jose Salvador; Chae, Young Kwang; Sindhu, Hemant; Diaz-Arrastia, Concepcion; Grzankowski, Kassondra; Azzi, Georges; Scalise, Carly Bess; Kalashnikova, Ekaterina; Nicosia, Brittany; Tekula, Shilpa; Aleshin, Alexey; ElNaggar, Adam C
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 2
• Page Start: A410
• Page End: A411
• Publication Date: 2022-10-20
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-ESGO.879
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: Immunotherapy has transformed cancer care. Unfortunately, responses within gynecologic malignancies have been modest when compared to other disease sites. Biomarkers for early determination of treatment benefit are urgently needed to spare unnecessary toxicity and cost. We evaluated if circulating tumor DNA (ctDNA) dynamics enable early detection of progressive disease (PD) and treatment response in patients with recurrent, gynecologic malignancies receiving immunotherapy. Methodology: Longitudinal plasma samples (n=138) were collected from 25 patients with recurrent cervical (N=6), endometrial (N=12), or ovarian (N=7) cancers who received immunotherapy. A personalized, tumor-informed multiplex PCR assay (Signatera TM bespoke mPCR NGS assay) was used for the detection of ctDNA in plasma samples. Results: Pre-treatment samples were available for 9 patients (78% ctDNA detection rate) and all 25 patients had on-treatment samples (68% ctDNA detection rate). Serially ctDNA negative patients (3/15 with imaging) had no evidence of disease on-treatment. ctDNA clearance was observed in 3 (cervical, N=2; endometrial, N=1) of the remaining 12 patients and correlated with clinical benefit. ctDNA decreased in additional 2 patients, both with objective response, while all 7 patients with increased ctDNA had PD. Increased ctDNA predicted PD prior to imaging by an average of ~2.5 months (lead-time) and was significantly associated with worse progression-free survival (PFS) compared to patients with decreased ctDNA (HR=0.14, 95%CI: 0.03–0.60; p<0.01). TMB and MSI status (binary) were not predictive of response in univariate (p=0.4, p=0.4) analyses. Conclusion ctDNA dynamics can accurately predict clinical benefit and allow for early prediction of PD in patients with advanced ovarian cancer receiving immunotherapy. Further study is warranted to evaluate the clinical utility of a personalized, tumor-informed ctDNA assay in patients with gynecologic malignancies undergoing systemic therapies.